Table 1.

Hereditary angioedema (HAE), a brief overview in the management of HAE in adults based on the Food and Drug Administration-approved options in the USA.^15–17

Acute management of HAE attacks
Preferred options	Intravenous C1-esterase inhibitor (C1-INH) concentrate (Berinert, Ruconest) Ecallantide (kallikrein inhibitor) Icatibant (bradykinin-receptor antagonist)
Alternatives	Fresh frozen plasma
P re procedural prophylaxis
No specific C1-INH concentrate is currently indicated in the USA (options are dependent on insurance formulary and coverage).
L ong-term prophylaxis
First-Iine options	Intravenous C1-INH concentrate (Cinryze) Subcutaneous C1-INH concentrate (Haegarda) Lanadelumab (antikallkrien monoclonal antibody)
Alternatives	Androgens Tranexamic acid*

*Tranexamic acid should be used when no other alternatives are available.